Is Summit Therapeutics a Millionaire Maker?

This company's promising cancer drug could challenge Merck's $25 billion crown jewel. The pharmaceutical industry is often about hitting home runs. Big pharmaceutical companies start small, and then a blockbuster product catapults them into the spotlight. Summit Therapeutics (SMMT 2.58%) has soared 1,000% over the past year on progress in developing a drug that could rival Merck's Keytruda, a product used to treat various cancers with over$ 25 billion in sales last year. Those who got in early have gotten r ...